LIK 066

Drug Profile

LIK 066

Alternative Names: LIK066

Latest Information Update: 29 May 2017

Price : $50

At a glance

  • Originator Novartis Pharmaceuticals Corporation
  • Class Antihyperglycaemics; Obesity therapies
  • Mechanism of Action Sodium-glucose transporter 1 inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 17 May 2017 Novartis plans a phase II trial for Type 2 diabetes mellitus patients, with Heart failure (NCT03152552) (EudraCT2016-003084-19)
  • 17 May 2017 Novartis plans a phase II trial for Polycystic ovary syndrome (NCT03152591)
  • 06 May 2017 Phase-II clinical trials in Obesity in Austria, Czech Republic, Hungary, Slovakia (PO) (EudraCT2016-002868-14; NCT03100058)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top